JPRN-UMIN000002686已完成2 期
A phase 2 study of cisplatin/pemetrexed followed by maintenance pemetrexed in patients with stage 3B or 4 non-squamous non-small-cell lung cancer. - A phase 2 study of cisplatin/pemetrexed followed by maintenance pemetrexed in patients with stage 3B or 4 non-squamous non-small-cell lung cancer.
Kinki-chuo chest medical center0 个研究点目标入组 35 人开始时间: 2009年11月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 74years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Histologically or cytologically confirned squamous cell lung cancer 2)Interstitial pneumonia or pulmonary fibrosis detectable on Chest X-ray 3) History of poorly controlled pleural effusion,pericardial effusion and ascites 4)Not appropriate to receive the folic acid and vitamin B12 formulation 5)SVC syndrome 6)Symptomatic brain metastases 7)History of active double cancer 8)Uncontrollable diabetes mellitus and hypertension 9)Diagnosed as liver cirrhosis by image findings or clinical laboratory 10)Suffers from an infectious disease to need antibiotic treatment 11)History of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,herat failure,etc within 6 months) 12)Pregnant female or sexually active males/females unwilling to use contraception during the protocol treatment 13)History of grave drug allergic reaction 14)Acute inflammatory disease 15)An agreement is not obtained for support therapy such as transfusion etc. 16)History of active psychological disease 17)Having the bleeding tendency which is clear in clinic 18)Taking continuous whole body administration (oral administration or intravenous administration) of steroid 19)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
招募中
不适用
A phase 2 study of cisplatin plus pemetrexed followed by maintenance pemetrexed in unresectable malignant pleural mesotheliomamalignant pleural mesotheliomaJPRN-UMIN000015226Kyoto Thoracic Oncology Research Group45
进行中（未招募）
不适用
Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study) - SoMe Studymalignant pleural mesothelioma (MPM)MedDRA version: 9.1Level: LLTClassification code 10059518Term: Pleural mesothelioma malignantEUCTR2007-005894-77-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
已完成
2 期
A Phase II study of Cisplatin and Pemetrexed for Advanced Non-Small(Non squamous cell)Lung CancerAdvanced Non-Small Cell (Non squamous cell)lung CancerJPRN-UMIN000002847Thoracic Medical oncology Thoracic center Cancer Institute Hospital Japanese Foundation for cancer research50
已完成
2 期
Phase II study of cisplatin, pemetrexed plus bevacizumab for EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell lung cancer)EGFR mutation negative or unknown stage III/IV non-small-cell lung cancer (non-squamous cell carcinoma)JPRN-UMIN000003855Departmnent of Thoracic Oncology Kanagawa Cancer Center25
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125